Pfizer

Oncology Research and Development Postdoctoral Program

Frank Loganzo, Ph.D.
Director

Education

Undergraduate: B.A. Biochemistry, Molecular & Cell Biology, Cornell University
Graduate: Ph.D. Biochemistry & Molecular Biology, Albany Medical College
Postdoctoral Training: Memorial Sloan-Kettering Cancer Center and Glaxo Wellcome, Inc.

Research Interests:

I lead a bioconjugation group and a bioassay screening group in ORU Pearl River, with the team’s primary goals of preparing antibody-drug conjugates (ADCs) for therapeutic programs, characterizing novel classes of payloads, and identifying new ADC linker-payloads.   One of my research interests is the characterization of drug resistance against ADCs & chemotherapeutics, and the lab has developed several cellular models of acquired resistance to ADCs.

Selected Publications


Loganzo F, Tan X, Sung M, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther, 14(4), 952-63 (2015).

Maderna A, Doroski M, Subramanyam C, Porte A, Leverett CA, Vetelino BC, Chen Z, Risley H, Parris K, Pandit J, Varghese AH, Shanker S, Song
C, Sukuru SCK, Farley KA, Wagenaar MM, Shapiro MJ, Musto S, Lam MH, Loganzo F, et al. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem, 57(24), 10527-10543 (2014).

He H, Ratnayake AS, Janso JE, He M, Yang HY, Loganzo F, et al. Cytotoxic spliceostatins from Burkholderia sp. and their semisynthetic analogues. J Natural Products, 77,  1864-1870 (2014).

Hooper AT, Loganzo F, May C, Gerber HP. Identification and development of vascular disrupting agents: Natural products that interfere with tumor growth. Chapter in: Natural Products and Cancer Drug Discovery, Ed: Frank E. Koehn. Springer, NY (2012).